FDA
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $62 at H.C. Wainwright
-
-
-
-
-
-
-
Leerink Partners Upgrades Agios Pharma (AGIO) to Outperform
-
-
-
-
-
-
-
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $52 at BofA Securities
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $56 at H.C. Wainwright
-
-
-
-
-
-
-
Agios Pharma (AGIO) Reports Phase 3 ACTIVATE-Kids Study of Mitapivat Met Primary Endpoint
-
-
-
-
-
-
-
Agios Pharma (AGIO): European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

